Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 310.00 GBp
Change Today 0.00 / 0.00%
Volume 7.9K
IDH On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 12:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

immunodiagnostic systems hld (IDH) Snapshot

Open
310.00 GBp
Previous Close
310.00 GBp
Day High
310.00 GBp
Day Low
305.00 GBp
52 Week High
06/24/14 - 537.50 GBp
52 Week Low
09/24/14 - 290.00 GBp
Market Cap
90.6M
Average Volume 10 Days
11.4K
EPS TTM
0.19 GBp
Shares Outstanding
29.2M
EX-Date
07/23/14
P/E TM
16.2x
Dividend
9.44 GBp
Dividend Yield
3.05%
Current Stock Chart for IMMUNODIAGNOSTIC SYSTEMS HLD (IDH)

Related News

No related news articles were found.

immunodiagnostic systems hld (IDH) Related Businessweek News

No Related Businessweek News Found

immunodiagnostic systems hld (IDH) Details

Immunodiagnostic Systems Holdings PLC, together with its subsidiaries, develops and supplies immunoassay kits and automated immunoanalyser technologies for use in research, medical, and pharmaceutical applications worldwide. The company offers immunodiagnostic kits for use in the investigation of bone, cartilage, growth, and hypertension areas, as well as calcium metabolism and chronic kidney disease; and distributes a range of antibodies, enzymes, and peptides for various specialty areas, including oncology, inflammation, neuroscience, and fertility. It also provides IDS-iSYS, an automated immunoassay system. The company was incorporated in 2004 and is headquartered in Boldon, the United Kingdom.

328 Employees
Last Reported Date: 06/23/14
Founded in 2004

immunodiagnostic systems hld (IDH) Top Compensated Officers

Chief Financial Officer, Group Finance Direct...
Total Annual Compensation: 223.0K GBP
Executive Officer of North American Operation...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

immunodiagnostic systems hld (IDH) Key Developments

Immunodiagnostic Systems Holdings plc Announces Executive Changes, Effective from April 01, 2015

Immunodiagnostic Systems Holdings plc announced that Patricio Lacalle has been appointed Chief Executive Officer and will join IDS as a Director effective 1 April 2015. Patricio is currently the CEO of Pulsion Medical Systems SE. In the four years which he has spent at Pulsion Patricio and his team were able to lead the company to international growth while significantly expanding the operating margin. Before Pulsion Patricio held a number of management positions at Forbo Adhesives and HB Fuller. On 1 April 2015, Burkhard Wittek, Executive Chairman, will revert to being Non-Executive Chairman.

Immunodiagnostic Systems Holdings plc Announces Executive Changes, Effect from January 4, 2015

Immunodiagnostic Systems Holdings plc announced that Patrik Dahlen, Chief Executive Officer, had given 12 months' notice to leave the Company, the Company announced that it has reached agreement with Patrik Dahlen for him to leave the Board and the Group with effect from January 4, 2015. The Company is undertaking a process to identify a new CEO. Until that appointment takes effect, Burkhard Wittek, the Company's Non-Executive Chairman, will become Executive Chairman, with effect from January 4, 2015. Upon the appointment of a new CEO, Burkhard Wittek will revert to being Non-Executive Chairman.

Immunodiagnostic Systems Holdings plc Announces Launch of Fully Automated 1,25 Dihydroxy Vitamin D Assay

Immunodiagnostic Systems Holdings plc announced that it has received European CE Mark declaration for the IDS-iSYS 1,25 VitDXp assay - a fully automated assay for use with the IDS-iSYS Multi-Discipline Automated System. The IDS-iSYS 1,25 VitDXp assay assesses 1,25 Dihydroxy Vitamin D status and deficiencies associated with renal disease and disorders of calcium metabolism. Market value of 1,25 Dihyroxy Vitamin D testing is estimated to be circa £15 million per annum in Europe. Available now, IDS offers laboratories evaluating calcium metabolism and Vitamin D deficiencies a comprehensive, fully automated solution.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDH:LN 310.00 GBp 0.00

IDH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDH.
View Industry Companies
 

Industry Analysis

IDH

Industry Average

Valuation IDH Industry Range
Price/Earnings 15.0x
Price/Sales 1.7x
Price/Book 1.0x
Price/Cash Flow 14.8x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNODIAGNOSTIC SYSTEMS HLD, please visit www.idsplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.